IN2014CN04935A - - Google Patents

Info

Publication number
IN2014CN04935A
IN2014CN04935A IN4935CHN2014A IN2014CN04935A IN 2014CN04935 A IN2014CN04935 A IN 2014CN04935A IN 4935CHN2014 A IN4935CHN2014 A IN 4935CHN2014A IN 2014CN04935 A IN2014CN04935 A IN 2014CN04935A
Authority
IN
India
Prior art keywords
tumor
tissues
probability
invention describes
gene
Prior art date
Application number
Inventor
Moni Abraham Kuriakose
Amritha Suresh
Original Assignee
Moni Abraham Kuriakose
Amritha Suresh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moni Abraham Kuriakose, Amritha Suresh filed Critical Moni Abraham Kuriakose
Publication of IN2014CN04935A publication Critical patent/IN2014CN04935A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention describes a method utilizing a set of genes or gene products whose altered expression in cancer tissue particularly head and neck cancer and other carcinomas or its adjacent normal tissues predicts (a) probability of recurrence in time after treatment (b) sensitivity or resistance to therapies or (c) probability of metastasis at the time of initial discovery of the tumor. Furthermore the invention describes methods of determining the molecular signature in tumor tissues tissues adjacent to the tumor or in saliva by using DNA microarray techniques quantitative real time PCR immunohistochemistry or other methods that are used for determining gene or gene product expression levels.
IN4935CHN2014 2011-12-31 2012-12-31 IN2014CN04935A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161631291P 2011-12-31 2011-12-31
PCT/IB2012/057844 WO2013098797A2 (en) 2011-12-31 2012-12-31 Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer

Publications (1)

Publication Number Publication Date
IN2014CN04935A true IN2014CN04935A (en) 2015-09-18

Family

ID=48698732

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4935CHN2014 IN2014CN04935A (en) 2011-12-31 2012-12-31

Country Status (3)

Country Link
US (1) US20140342946A1 (en)
IN (1) IN2014CN04935A (en)
WO (1) WO2013098797A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520451A (en) 2008-05-14 2011-07-21 ダームテック インターナショナル Diagnosis of melanoma and Nikko Kuroko by nucleic acid analysis
CN103525916B (en) * 2013-09-24 2016-06-15 浙江大学医学院附属第四医院 The test kit of assessment prognosis of HCC and the application of RFFL
US20180161300A1 (en) 2015-05-11 2018-06-14 Yeda Research And Development Co., Ltd. Citrin inhibitors for the treatment of cancer
WO2017004153A1 (en) * 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
KR101744397B1 (en) * 2015-07-07 2017-06-08 울산대학교 산학협력단 Use of Uba6 or Use1 as a diagnostic marker of cancer
US11371099B2 (en) 2015-11-30 2022-06-28 Mayo Foundation For Medical Education And Research HEATR1 as a marker for chemoresistance
CA2932910A1 (en) * 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
CN106191295B (en) * 2016-08-30 2019-07-16 梁燕华 Purposes of the SHARPIN gene in preparation diagnosis application on human skin tumor reagent
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
AU2017382234A1 (en) 2016-12-23 2019-07-04 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
TWI783957B (en) 2016-12-23 2022-11-21 美商伊繆諾金公司 Immunoconjugates targeting adam9 and methods of use thereof
MY192920A (en) 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
CN107312843B (en) * 2017-07-06 2020-08-28 北京大学深圳医院（北京大学深圳临床医学院） Application of KRBA1 gene mutation in preparation of breast cancer detection kit
WO2019022586A2 (en) * 2017-07-28 2019-01-31 주식회사 레모넥스 Pharmaceutical composition for preventing or treating liver cancer
CN116898870A (en) * 2017-07-28 2023-10-20 雷莫内克斯生物制药有限公司 Pharmaceutical composition for preventing or treating liver cancer
TWI793151B (en) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN107621543B (en) * 2017-08-30 2019-10-01 福建师范大学 Application, prognosis in hcc assessment kit and method of the KRBA1 albumen after preparing Liver Cancer Operation in prognosis evaluation reagent kit
WO2019146841A1 (en) * 2018-01-25 2019-08-01 가톨릭대학교 산학협력단 Biomarker for diagnosis and prognostic prediction of liver cancer and use thereof
KR102270926B1 (en) * 2018-01-25 2021-06-30 주식회사 네오나 A composition for preventing and treating liver cancer comprising BANF1, PLOD3 or SF3B4
KR102025005B1 (en) * 2018-01-25 2019-09-24 가톨릭대학교 산학협력단 Biomarker for early diagnosis of hepatocellular carcinoma in precancerous lesion and use thereof
SG11202012257VA (en) 2018-06-26 2021-01-28 Immunogen Inc Immunoconjugates targeting adam9 and methods of use thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
SG11202011872QA (en) 2018-07-10 2021-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
CN109722482A (en) * 2019-01-23 2019-05-07 宁波大学 Application of the molecular marker SKA2 in metastatic clear cell carcinoma of kidney
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
KR102203850B1 (en) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 Composition for diagnosing or prognosising gliomas and a method for providing information for gliomas using same marker
KR102042710B1 (en) * 2019-07-02 2019-11-08 의료법인 성광의료재단 Biomarkers for the diagnosis of ovarian cancer associated with immune checkpoints
CN111308074B (en) * 2019-12-12 2022-11-01 中山大学附属第三医院 Application of diagnosis marker for detecting hepatocellular carcinoma and screening or auxiliary diagnosis product
EP4267739A1 (en) 2020-12-23 2023-11-01 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors
CN113238051A (en) * 2021-02-24 2021-08-10 深圳市人民医院 Application of human-derived MOB1 protein
CN112980955A (en) * 2021-03-05 2021-06-18 南昌大学第二附属医院 Application of EMILIN2 as drug-resistant detection, treatment and prognosis molecular target of glioma temozolomide
EP4304660A1 (en) 2021-03-08 2024-01-17 ImmunoGen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
CN113917156A (en) * 2021-09-30 2022-01-11 复旦大学附属中山医院 Application of Hint2 in preparation of medicine for treating or diagnosing heart failure
CN116312802B (en) * 2023-02-01 2023-11-28 中国医学科学院肿瘤医院 Application of characteristic gene TRIM22 in preparation of reagent for regulating and controlling breast cancer related gene expression
CN116617245B (en) * 2023-02-17 2023-11-10 新乡医学院 UTP11 inhibitors and their use in tumor inhibition
CN117089621A (en) * 2023-09-28 2023-11-21 上海爱谱蒂康生物科技有限公司 Biomarker combinations and their use in predicting colorectal cancer efficacy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281091A1 (en) * 2003-07-07 2006-12-14 Lavedan Christian N Genes regulated in ovarian cancer a s prognostic and therapeutic targets
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
CA2745961A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer

Also Published As

Publication number Publication date
WO2013098797A2 (en) 2013-07-04
US20140342946A1 (en) 2014-11-20
WO2013098797A3 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
IN2014CN04935A (en)
Villanueva et al. The contribution of epigenetics to cancer immunotherapy
Dugger et al. Drug development in the era of precision medicine
Batagov et al. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3′-untranslated regions
Gorenchtein et al. MicroRNAs in an oral cancer context–from basic biology to clinical utility
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
Chen et al. miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3
Marsh et al. Histones and their modifications in ovarian cancer–drivers of disease and therapeutic targets
Menyhart et al. A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer
EP3633041A3 (en) Synthetic combinatorial aav capsid library for targeted gene therapy
MX2021000210A (en) Methods and products for transfecting cells.
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
WO2011122857A3 (en) Composition for predicting prognosis of breast cancer, and kit containing same
Arrighetti et al. Mirnas as therapeutic tools and biomarkers for prostate cancer
MX2013008252A (en) Prognostic signature for colorectal cancer recurrence.
Fujiwara et al. MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers
Kunz et al. MicroRNA-21 versus microRNA-34: lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact
Gao et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
WO2012131670A3 (en) Methods for lung cancer clasification
Bertoni et al. Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma
Huang et al. Effect of miR‑146a‑5p on tumor growth in NSCLC using chick chorioallantoic membrane assay and bioinformatics investigation
Lu et al. Transcriptome sequencing investigated the tumor-related factors changes after T. gondii infection
EA201290107A1 (en) METHOD FOR DETERMINING A PATIENT AS A SUSTAINABLE OR NOT SUSTAINABLE FOR IMMUNOTHERAPY
Shin et al. MUDENG expression profiling in cohorts and brain tumor biospecimens to evaluate its role in cancer
Felip et al. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?